Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy

Journal of Clinical Oncology

Volumn 22, Issue 8, 2004, Pages 1480-1490

  Garcia Carbonero, R ^a   Supko, J G ^a   Manola, J ^a   Seiden, M V ^a   Hannon, D ^a   Ryan, D P ^a   Quigley, M T ^a   Merriam, P ^a   Canniff, J ^a   Goss, G ^a   Matulonis, U ^a   Maki, R G ^a   Lopez, T ^a   Puchalski, T A ^a   Sancho, M A ^a   Gomez, J ^a   Guzman, C ^a   Jimeno, J ^a   Demetri, George D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; SIDE EFFECT; SOFT TISSUE SARCOMA; TRANSAMINITIS; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; ADULT; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; FEMALE; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TETRAHYDROISOQUINOLINES;

EID: 2342461682     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.098     Document Type: Article

References (52)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
2. Morton DL, Antman KH, Tepper J: Soft tissue sarcomas, in Holland JF, Bast RC, Morton DL, et al (eds): Cancer Medicine (ed 4). Philadelphia, PA, Williams & Wilkins, 1997, pp 2559-2592
3. Brennan MF, Casper ES, Harrison LB. Soft tissue sarcoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, pp 1738-1788
4. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
5. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311-321, 1987
6. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
7. Buesa JM, Mouridsen HT, Oosteron ATV, et al: High-dose DTIC in advanced soft-tissue sarcoma in the adult: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 2:307-309, 1991
8. Mouridsen HT, Bastholt L, Somers R, et al: Adriamycin versus epirubicin in advanced soft tissue sarcomas: A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23:1477-1483, 1987
9. Brenner J, Magill GB, Sordillo PP, et al: Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma. Cancer 50:2031-2033, 1982
10. Goldstein D, Cheuvart B, Trump DL, et al: Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 13:420-423, 1990
11. Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2081-2086, 2000
12. Casper ES, Waltzman RJ, Schwartz GK, et al: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 16:442-446, 1998
13. Bramwell VH, Eisenhauer EA, Blackstein M, et al: Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 6:847-849, 1995
14. Fidias P, Demetri G, Harmon D: Navelbine shows activity in previously treated sarcoma patients: Phase Il results from MGH/Dana-Farber/Partners Cancer Care study. Proc Am Soc Clin Oncol 17:513a. 1998 (abstr 1977)
15. Spath-Schwalbe E, Genvresse I, Koschuth A, et al: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11:325-329, 2000
16. Nielsen OS, Judson I, van Hoesel Q, et al: Effect of high-dose ifosfamide in advanced soft tissue sarcomas: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61-67, 2000
17. Van Oosterom AT, Mouridsen HT, Nielsen OS, et al: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406, 2002
18. Rinehart K, Holt T, Fregeau N, et al: Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 55:4512-4515, 1990
19. Jimeno J, Faircloth G, Cameron L, et al: Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs Future 21: 1155-1165, 1996
20. Guan Y, Sakai R, Rinehart K, et al: Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate ecteinascidia turbinata. J Biomol Struct Dyn 10:793-818, 1993
21. Pommier Y, Kohlhagen G, Bailly C, et al: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate ecteinascidia turbinata. Biochemistry 35:13303-13309, 1996
22. Moore BM, Seaman FC, Hurley LH: NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 119:5475-5476, 1997
23. Zewail-Foote M, Hurley LH: Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J Med Chem 42:2493-2497, 1999
24. Takebayashi Y, Pourquier P, Zimonjic DB, et al: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961-966, 2001
25. Minuzzo M, Marchini S, Broggini M, et al: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97:6780-6784, 2000
26. Jin S, Gorfajn B, Faircloth G, et al: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDFH activation. Proc Natl Acad Sci USA 97:6775-6779, 2000
27. Zwicker J, Muller R: Cell-cycle regulation of gene expression by transcriptional repression. Trends Genet 13:3-6, 1997
28. D'Incalci M, Erba E, Faretta M, et al: New drugs of marine origin. Ann Oncol 7:34, 1996 (suppl 1)
29. Hendriks HR, Fiebig HH, Giavazzi R, et al: High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10:1233-1240, 1999
30. Valoti G, Nicoletti MI, Pellegrino A, et al: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977-1983, 1998
31. Izbicka E, Lawrence R, Raymond E, et al: In vitro antitumor activity of the novel marine agent, ecteinascidin-743(ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981-987, 1998
32. Van Kesteren C, Twelves C, Bowman A, et al: Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13:381-393, 2002
33. Taamma A, Misset JL, Riofrio M, et al: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256-1265, 2001
34. Villalona-Calero MA, Eckhardt SG, Weiss G, et al: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 8:75-85, 2002
35. Ryan DP, Supko JG, Eder JP Jr, et al: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72 hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7:231-242, 2001
36. The Cancer Therapy Evaluation Program: Common toxicity criteria manual, 8/99 update. http://ctep.info.nih.gov/CTC3/CTC-Manual.htm
37. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48., Geneva, Switzerland, World Health Organization, 1979
38. Mizuta E, Tsubotani A: Preparation of mean drug concentration-time curves in plasma: A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull 33: 1620-1632, 1985
39. Lam FC, Hung CT, Perrier DG: Estimation of variance for harmonic mean half-lives. J Pharm Sci 74:229-231, 1985
40. Lacey LF, Keene ON, Pritchard JF, et al: Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed? J Biopharm Stat 7:171-178, 1997
41. Simon R: Optimal two-stage designs for clinical trials. Control Clin Trials 10:1-10, 1989
42. Atkinson EN, Brown BW: Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 41:741-744, 1985
43. Le Cesne A, Blay JY, Judson I, et al: ET-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial. Proc Am Soc Clin Oncol 20:353a, 2001 (abstr 1407)
44. Delaloge S, Yovine A, Taamma A, et al: Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients-Preliminary evidence of activity. J Clin Oncol 19: 1248-1255, 2001
45. Gómez J, López Lázaro L, Guzmán C, et al: Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol 19:187a, 2000 (abstr 727)
46. Reid JM, Kuffel MJ, Ruben SL, et al: Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 8:2952-2962, 2002
47. Reid JM, Kuffel MJ, Squillace DP, et al: Characterization of the in vitro metabolism, pharmacokinetics, and biliary excretion of ecteinascidin 743 (NSC 648766) in male and female rats. Ann Oncol 9:S50, 1998 (suppl 2)
48. Antman K, Crowley J, Balcerzak S, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
49. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676-2684, 2000
50. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150-157, 1999
51. Mentzel T, Fletcher CD: Lipomatous tumours of soft tissues: An update. Virchows Arch 427:353-363, 1995
52. Takahashi N, Li WW, Banerjee D, et al: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251-3257, 2001